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TERMINOLOGY
CLINICAL CLARIFICATION
Opioid toxicity results in severe—sometimes fatal—effects that most commonly occur after overdose, which can be
intentional or accidental 1
•
Primary toxic effect of opioid overdose is decreased rate and depth of respiration leading to pulmonary edema 1•
May result in death from hypoxia and respiratory arrest before pulmonary edema develops○
Effects on other organs include hypotension, bradycardia, and decreased body temperature 1•
CLASSIFICATION
Toxicity caused by short-acting opioids, such as:•
Morphine sulfate○
Fentanyl○
Fentanyl analogs–
Carfentanyl is the most potent analog (100 times that of fentanyl) and is used as an anesthetic for large animals□
Analogs with no licensed medical use include acetylfentanyl and butyrylfentanyl□
Oxycodone○
Hydrocodone○
Codeine○
Heroin○
Toxicity caused by longer-acting and delayed-release opioids, including:•
Extended-release morphine sulfate○
Methadone○
Oxymorphone○
Toxicity caused by opioid receptor agonist-antagonist drugs, such as:•
Agonist at one opioid receptor, antagonist at a different opioid receptor○
Pentazocine–
Butorphanol–
Nalbuphine–
Dezocine–
Partial agonist at a single opioid receptor○
Buprenorphine–
Meptazinol–
DIAGNOSIS
CLINICAL PRESENTATION
History•
History of nonprescribed opioid use or abuse 2○
Medical records may indicate previous use or abuse–
Family or friends may confirm opioid use–
Needles or other paraphernalia found near patient–
History of prescribed opioid use 2○
Pills, pill bottles, or drug paraphernalia found near patient–
Common symptoms even without any available history 2○
Apnea–
Depressed consciousness–
Can range from drowsiness to coma□
Physical examination•
Common signs 3○
Depressed respiratory rate is the most specific sign–
Respiratory rate of 12 breaths or fewer per minute, with stupor, is highly suggestive of acute opioid toxicity,
especially when accompanied by miosis and/or depressed consciousness
□
Reduced size and reactivity of pupils–
Pupil constriction to less than 2-mm diameter 4□
Not always present, particularly if opioids were ingested along with other substances□
Hypotension, bradycardia, and hypothermia are usually present 3–
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Other examination findings 3○
Skin–
Evidence of fentanyl patches 1□
Needle track marks□
Recent injection marks are small, red, inflamed, or surrounded by slight bruising□
Old injection sites show pigmentation change and atrophied skin□
Neurologic–
Seizures often are associated with overdose of tramadol, propoxyphene, and meperidine, particularly if used
concomitantly with medicines that lower seizure thresholds 1
□
Mucous membrane 3–
Mucous membrane cyanosis is a late sign of hypoxia and hypotension□
Pulmonary–
Pulmonary edema in patients with apnea or severe bradypnea□
Rales and frothy sputum are a late sign of severe opioid toxicity 1□
Cardiac–
QTc prolongation may occur in some patients receiving methadone, increasing chance of developing a ventricular
arrhythmia, particularly torsades de pointes 5
□
CAUSES AND RISK FACTORS
Causes•
Overdose of opioid drugs 2○
Opioid drugs are substances that bind to 1 or more of the 4 opioid receptors (δ, κ, μ, and nociceptin receptors)–
Toxicity is not necessarily dependent on dose of opioid used, but instead depends on individual tolerance at time of
exposure
–
Tolerance may be dramatically different in patient subpopulations□
More overdose deaths are due to prescription opioids than nonprescription forms 6–
Commonly prescribed opioids 7□
Hydrocodone□
Oxycodone□
Morphine□
Codeine□
Hydromorphone□
Oxymorphone□
Methadone□
Fentanyl patch□
Tapentadol□
Diphenoxylate□
Fentanyl□
Commonly prescribed opioid receptor agonist/antagonist or partial-agonist drugs□
Pentazocine□
Butorphanol□
Nalbuphine□
Dezocine□
Buprenorphine□
Meptazinol□
Most common nonprescription opioids□
Heroin□
Fentanyl (diverted or illicitly produced; typically added to heroin)□
Carfentanyl (diverted from veterinary sources; typically added to heroin)□
Loperamide (in supratherapeutic doses)□
Overdose of buprenorphine usually does not cause lethal respiratory depression in adults unless administered
intravenously or combined with another respiratory depressant, but lethal respiratory depression can occur in elderly
or weak patients 8
○
Death from buprenorphine in children results from respiratory depression, usually following unintentional exposure
secondary to medication being stored in sight, accessed from a bag or purse, or not being stored in its original
packaging 9
–
Effects of toxic metabolites 10○
Normeperidine from meperidine: lowers seizure threshold and accumulates with repeated dosing–
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Morphine-3-glucuronide from morphine: lowers seizure threshold and may be responsible for myoclonus and
allodynia
–
Risk factors and/or associations•
Age○
Higher incidence of opioid poisoning deaths in those aged 25 to 64 years, with highest incidence among those aged
45 to 54 years 11
–
Advanced age is associated with reduced clearance of morphine, fentanyl, codeine, and oxymorphone, which
increases risk of overdose (and requires more caution with prescribing) 10
–
Children are more likely than adults to experience respiratory depression and death after unintentional exposure to
agonist/antagonists such as buprenorphine 9, 12
–
Children may be more sensitive to codeine dosing and can be accidentally overdosed owing to existence of rapid
metabolizers of the prodrug codeine to the active drug morphine 13
–
Avoid giving codeine to breastfeeding mothers□
Sex○
Incidence higher in men 2–
Ethnicity/race○
Death rates in white populations are 4 times higher than in Hispanic or black populations 11–
Other risk factors/associations○
Opioid toxicity is most highly associated with people who are prescribed high doses of opioid analgesics (over 100
mg of morphine or equivalent per day) 14
–
Also associated with people who seek care from multiple physicians or receive early refills 2–
Risk of distribution to others□
Prescription opioid death rates are highest in rural populations 2, 11–
Heroin death rates are highest in large central metropolitan areas 2–
Populations at greatest risk for opioid toxicity 2–
People with mental illness□
People who report long-term medical use of opioids□
People who report nonmedical use (ie, use without a prescription or medical need) of opioids in the past month□
Hepatic impairment 10–
Especially important to consider when using oxycodone, morphine, or oxymorphone□
Lower risk of toxicity with fentanyl and methadone□
Renal impairment 10–
Particularly important when using morphine, hydromorphone, and other opioids with active metabolites□
Less risk with fentanyl and methadone□
DIAGNOSTIC PROCEDURES
Primary diagnostic tools•
Primary diagnosis is based on: 15○
Classic symptoms of opioid overdose–
Respiratory depression, often accompanied by central nervous system depression and miosis□
Responsiveness to naloxone–
Laboratory•
Urine toxicology tests 15○
Screen for acetaminophen levels–
Do not rely on toxicology screens for the initial diagnosis or management of suspected opioid overdose–
Positive screen for opioids does not confirm toxicity–
Although positive toxicology results can indicate presence of opioids, negative results do not necessarily mean
absence of opioids
–
Some opioids, such as fentanyl, may not be detectable using typical toxicology screening methods□
Imaging•
Obtain chest radiographs in opioid-toxic patients with rales or hypoxia to evaluate for pulmonary edema or aspiration
pneumonia
○
Functional testing•
Can use ECG to monitor bradycardia 15○
QTc prolongation may occur in some patients receiving methadone, increasing the chance of developing a ventricular
arrhythmia, particularly torsades de pointes 5
○
Doses above 100 mg daily produce a dose-dependent QTc prolongation–
Regular monitoring of the QTc is recommended for patients receiving therapy who have baseline prolonged QT
intervals greater than 501 milliseconds
□
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QTc prolongation also may occur with loperamide toxicity 16–
DIFFERENTIAL DIAGNOSIS
Most common•
Clonidine and oxymetazoline toxicity (particularly in pediatric patients)○
Both drugs are centrally acting α₁-blockers that cause depressed mental status, bradycardia, hypotension, and
miosis
–
Partial response to naloxone is common–
No easy or consistent way to differentiate from opioid toxicity□
Urine test for these drugs is typically only available at reference laboratories□
Results will not change patient management□
Most children with clonidine or oxymetazoline toxicity will be treated as opioid toxic and vice versa–
Nonresponse to naloxone is the best way to determine that the diagnosis is likely something other than opioid
toxicity, but eliciting a response in patients with opioid toxicity may require large doses of naloxone
–
Acute subdural hematoma 15○
Common presentation is depressed mental status–
CT scan results differentiate pure opioid toxicity from subdural hematoma–
Other central nervous system depressant toxicity (eg, alcohol, barbiturate, benzodiazepine, cannabinoid) 17○
Cannot differentiate easily by symptoms alone–
Differentiate by ineffectiveness of naloxone–
Combined with quantitative alcohol serum levels, narrows diagnostic considerations□
Meningitis and encephalitis○
Both present with confusion and depressed mental status–
Additional symptoms include headache, vomiting, and fever□
Both do not respond to naloxone–
Differentiate by using CT scan to reveal meningeal inflammation and using lumbar puncture to show evidence of
infection
–
Hypoglycemia○
Presents with confusion and depressed mental status–
Differentiate using a bedside blood glucose test and response to glucose administration–
TREATMENT
GOALS
Reverse opioid toxicity•
Treat with reversal agent○
Secure airway○
Restore respiratory status○
Reverse central nervous system depression○
Avoid precipitating withdrawal•
DISPOSITION
Admission criteria•
Admit children aged 3 years or younger who were exposed to opioids other than immediate-release formulations for
24-hour observation if ingestion of agents is suspected from history but cannot be confirmed 18
○
Respiratory depression○
Occurs after nonresponse to naloxone or during resedation after naloxone wears off and continued observation in
the emergency department is unavailable
–
Criteria for ICU admission 19, 1○
Patients whose toxicity is due to long-lasting and extended-release opioids–
Long-lasting and extended-release opioids cause resedation after naloxone wears off□
Require prolonged observation for respiratory depression and airway compromise□
Patients who require a naloxone infusion–
Patients who require orotracheal intubation–
Recommendations for specialist referral•
Refer to medical toxicologist for specialty management of opioid toxicity○
Refer to pain or addiction specialist to prevent recurrence and treat addiction○
TREATMENT OPTIONS
First priority is to restore respiration using a bag-valve mask until naloxone can be administered 1•
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Advanced airway intervention is rarely required unless there are coingestants or other illnesses or injuries•
Observe for and remove any fentanyl patches•
Drug treatment is the same regardless of causative opioid•
Naloxone therapy is the standard treatment of opioid toxicity 1○
Empiric administration to unresponsive patients with suspected opioid overdose is recommended to reverse
respiratory depression; however, only small doses may be required. Larger doses may precipitate withdrawal
unnecessarily
–
Small doses also may be used for diagnostic purposes for patients with decreased level of consciousness of
unknown cause
–
Naloxone prescriptions or access to OTC naloxone is an important treatment option for high-risk individuals○
Drug therapy•
Naloxone 1○
Dose is empiric and depends on the amount of opioid the patient received or has taken–
IV administration is most common and preferable method of delivery–
IV naloxone continuous infusion is difficult and has several drawbacks□
Difficult to titrate adequate dose to maintain adequate respiration while avoiding precipitating withdrawal□
Recommended infusion strategy of hourly dose to match dose required to reverse apnea has not been
validated
□
Relying on an IV infusion of drug to maintain ventilation□
IV catheters can become kinked, be pulled out, or become otherwise dysfunctional□
Patients still require ICU admission for monitoring□
Use intramuscular, intranasal, or pulmonary administration when IV is not an option–
Do not administer orally because it has high first-pass metabolism rate–
Observation must last longer than the expected elimination time for naloxone. Minimum observation time for
naloxone is 1 to 2 hours, but observe patient 4 to 6 hours in case there are coingestants 20, 21
–
Toxic effects often reappear within 30 minutes of naloxone dosing, requiring further naloxone because it has a
short half-life
–
Gradual titration of naloxone dose is preferred over isolated larger doses to avoid precipitating withdrawal–
Opioids that require larger doses of naloxone 20–
Natural opium derivatives□
Codeine□
Methadone□
Synthetic opiates□
Diphenoxylate□
Propoxyphene□
Mixed opioid agonist-antagonists□
Pentazocine□
Butorphanol□
Nalbuphine□
Partial agonist□
Buprenorphine□
Intermittent IV, intramuscular, subcutaneous, or intraosseous dosage (standard syringe)–
Naloxone Hydrochloride Solution for injection; Neonates: 0.1 mg/kg/dose IV/IM is recommended in clinical
guidelines; may require repeated doses. FDA-approved labeling recommends 0.01 mg/kg/dose IV, IM, or
subcutaneously initially; may repeat every 2 to 3 minutes.
□
Naloxone Hydrochloride Solution for injection; Infants and Children younger than 5 years or weighing 20 kg or
less: 0.1 mg/kg/dose IV/IO (PALS recommendation); may require repeated doses. FDA-approved labeling
recommends 0.01 mg/kg/dose IV, IM, or subcutaneously initially; may repeat every 2 to 3 minutes.
□
Naloxone Hydrochloride Solution for injection; Children and Adolescents 5 to 17 years or weighing more than 20
kg: 2 mg IV/IO (PALS recommendation); may require repeated doses. FDA-approved labeling recommends 0.01
mg/kg/dose IV, IM, or subcutaneously initially; may repeat every 2 to 3 minutes.
□
Naloxone Hydrochloride Solution for injection; Adults: 0.4 to 2 mg IV, IM, or subcutaneously, up to a total dose of
10 mg; doses may be repeated every 2 to 3 minutes PRN. In emergency settings, guidelines recommend 0.4 to 2
mg IV; alternatively, 0.4 to 0.8 mg may be given IM/subcutaneously if systemic perfusion is adequate.
□
High doses (5-10 mg ) of naloxone have been required to reverse buprenorphine-induced respiratory
depression; it may take up to 3 hours before maximum reversal is observed 22, 23
□
Prompt consultation with a medical toxicologist is prudent□
Published April 21, 2016; Updated May 31, 2019 
Copyright © 2020 Elsevier
Opioid toxicity
Giving bolus doses of naloxone, followed by an IV infusion (eg, 4 mg/hour) has been described to treat
buprenorphine overdose 22
□
Endotracheal dosage–
Naloxone Hydrochloride Solution for injection; Infants and Children younger than 5 years or weighing 20 kg or
less: Optimal ET dosage has not been determined; a dose of 2 to 3 times the IV dose has been recommended
(equivalent to 0.2 to 0.3 mg/kg/dose ET).
□
Naloxone Hydrochloride Solution for injection; Children and Adolescents 5 to 17 years or weighing more than 20
kg: Optimal ET dosage has not been determined; a dose of 2 to 3 times the IV dose has been recommended
(equivalent to 4 to 6 mg/dose ET).
□
Naloxone Hydrochloride Solution for injection; Adults: Optimal ET dosage has not been determined. In
emergency settings, guidelines recommend 0.4 to 2 mg via ET tube.
□
Intranasal dosage (Narcan nasal spray)–
Naloxone Hydrochloride Nasal spray, solution; Adults, Adolescents, Children, Infants, and Neonates: 1 spray (2 mg
or 4 mg of naloxone) by intranasal administration. Seek immediate medical attention after administration of the
first dose. May repeat dose in alternate nostrils every 2 to 3 minutes as needed; each device contains a single
dose. Monitor closely until emergency medical personal arrive; continue to monitor pediatric patients for at least
24 hours.
□
Continuous IV or intraosseous infusion dosage–
Naloxone Hydrochloride Solution for injection; Neonates, Infants, Children, and Adolescents: Limited data
available. If repeated intermittent doses are required, calculate initial infusion rate based on effective
intermittent dose; use two-thirds up to the full intermittent dose as initial hourly infusion rate (i.e., if a 0.02 mg/kg
IV dose was effective, initiate infusion at 13 to 20 mcg/kg/hour [0.013 to 0.02 mg/kg/hour]). Titrate as needed. A
continuous infusion rate of 2 to 160 mcg/kg/hour IV/IO has been suggested; however, most reports have utilized
24 to 44 mcg/kg/hour IV. When appropriate, wean in 25% increments while closely monitoring patient.
□
Naloxone Hydrochloride Solution for injection; Adults: Loading dose of 0.005 mg/kg IV followed by 0.0025
mg/kg/hour IV.
□
Naloxone can precipitate withdrawal symptoms, including: 24○
Anxiety, irritability, and restlessness–
Patients can become violent and uncooperative–
Goose flesh–
Hot and cold sweats–
Muscle, bone, and joint aches–
Tremor–
Nausea, vomiting, and diarrhea–
Increased resting pulse rate–
Nondrug and supportive care•
For apnea of fewer than 12 breaths per minute 1○
Provide ventilation with a bag-valve mask–
Perform chin-lift and jaw-thrust maneuvers to diminish hypercapnia–
Procedures○
Orotracheal intubation 1–
General explanation□
Insertion of a tube into the trachea to restore respiration□
Safely ensures oxygenation and ventilation while providing protection against aspiration□
Indication□
To gain definitive control of the airway to restore respiration□
Special populations•
Children○
Overdose characterized by: 1–
Unexpectedly severe poisoning based on dose received□
Prolonged toxic effects□
Admit children aged 3 years or younger who were exposed to opioids other than immediate-release formulations
for 24-hour observation if ingestion of agents is suspected from history but cannot be confirmed 18
–
Children who ingest opioids may require larger doses of naloxone because they often ingest a higher dose than
adults per kilogram of body weight 1
–
Elderly people○
Age-related changes in physiology and body composition may cause persistent intoxication 1–
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MONITORING
For patients with opioid toxicity, it is mandatory to monitor respiratory adequacy and cardiovascular stability•
Use pulse oximetry or end-tidal CO₂ to monitor respiration○
Use periodic (every 15 minutes) blood pressure monitoring to assess for hypotension○
COMPLICATIONS AND PROGNOSIS
COMPLICATIONS
Respiratory depression and apnea•
Apneic patients who receive naloxone frequently develop noncardiogenic pulmonary edema 1○
Central nervous system depression with airway compromise•
Vomiting can result in aspiration of gastric contents into the lungs○
Head trauma or brain injury due to falls related to loss of consciousness•
Multiple complications can occur secondary to prolonged hypotension, bradycardia, and hypothermia•
Death may occur in severe situations•
Accidental overdose can occur when nonpharmaceutical agents contain unexpected substances such as fentanyl or its
analogs
○
PROGNOSIS
Recurrence is likely in patients with opioid abuse history 2•
In 1 study, approximately 1% of patients with nonfatal opioid overdoses went on to have fatal overdoses within 1 year 25•
Mortality rate is 5.1 per 100,000 with opioid analgesics 26•
SCREENING AND PREVENTION
SCREENING
PREVENTION
Provider education and implementation of prescription drug monitoring programs assist in avoiding the following: 27, 28•
Inappropriate prescription of opioid analgesics○
Chronic prescription of opioids for acute pain○
Prescription of high-dose opioid analgesics○
Use prescription and insurance data to screen and reduce opioid prescription for: 28, 27•
Patients seeking care from multiple physicians○
Patients obtaining early refills○
At risk for providing opioids to others–
Increase availability of opioid-dependence treatment, especially office-based medication-assisted treatment with
buprenorphine/naloxone 27, 28
•
To decrease risk of opioid toxicity death, distribute naloxone and promote education about its use in communities where
opioid toxicity is likely 27, 28
•
Provide naloxone to patients receiving chronic opioid therapy, particularly those requiring higher doses, and train patient
and family members how to administer intranasally when overdose is suspected 29, 27, 28
•
Refer opioid abusing or dependent patients to Narcotics Anonymous or similar support programs 27, 28•
Inpatient and outpatient rehabilitation counseling is an important aspect of prevention○
SYNOPSIS
KEY POINTS
Opioid toxicity results in severe—sometimes fatal—effects that most commonly occur after overdose, which can be
intentional or accidental
•
Opioid toxicity causes respiratory depression, generally accompanied by depressed consciousness and miosis•
Diagnosis is made based on these 3 primary symptoms, which may not always present together, paired with a positive
response to naloxone
○
Opioid toxicity is often coupled with ingestion of other substances, such as acetaminophen or ethanol•
Restore respiration using a bag-valve mask until naloxone can be administered•
IV naloxone, a competitive opioid antagonist, is the gold standard reversal agent•
Continuously observe patients receiving naloxone because it has a short half-life•
Observation must last longer than the expected elimination time for naloxone. Minimum observation time for
naloxone is 1 to 2 hours, but observe patient 4 to 6 hours in case there are coingestants
○
Naloxone, although necessary, can cause withdrawal symptoms, which can be stressful to patients and caregivers;
cautious titration to desired effect (reversal of respiratory suppression) is recommended
•
Recurrence is likely in patients with opioid use disorder history•
Published April 21, 2016; Updated May 31, 2019 
Copyright © 2020 Elsevier
Opioid toxicity
URGENT ACTION
First priority is to restore respiration•
If symptoms are present, begin treating with naloxone to reverse opioid toxicity; do not wait for drug screen or
immunoassay results to confirm diagnosis
•
Admit to ICU if patient is intoxicated by long-lasting opioids, has recurrent respiratory depression, requires naloxone
infusion, or requires intubation
•
PITFALLS
Naloxone can precipitate opioid withdrawal and is titrated for best effect•
Do not attribute altered mental status to opioid toxicity solely based on positive drug screen results; the screen is
qualitative not quantitative
•
May present along with head trauma, which can hinder restoration of consciousness○
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